Skip to main content

Table 1 Main characteristics

From: Cytokeratin 18 can help predict liver fibrosis in HCV infected patients with type 2 diabetes mellitus

Parameter Training (n = 132) Validation (n = 120) P value
Sex    .614
 No. of men 72 (54.5) 61 (50.8)  
 No. of women 60 (45.5) 59 (49.2)  
Age    .703
 < 60 (years) 76 (57.6) 72 (60.0)  
 ≥ 60 (years) 56 (42.4) 48 (40.0)  
BMI 23.86 ± 3.06 23.67 ± 2.88 .618
Laboratory findingsa    
 WBC (109/L) 5.45 ± 2.15 5.20 ± 2.04 .354
 FBG (mmol/L) 8.6 ± 4.2 9.3 ± 5.4 .250
 FINS (mIU/L) 14.86 ± 10.37 16.33 ± 11.49 .287
 AST (IU/mL) 57.59 ± 68.80 69.88 ± 121.65 .319
 ALT (IU/mL) 86.45 ± 145.88 87.22 ± 169.00 .969
 GGT (IU/mL) 92.16 ± 118.81 77.40 ± 106.36 .302
 ALP (IU/mL) 98.39 ± 60.50 87.78 ± 67.94 .191
 Platelet count (109/L) 151.96 ± 59.70 148.97 ± 68.49 .711
 Cholesterol (mmol/L) 3.96 ± 1.00 4.04 ± 0.92 .527
 TG (mmol/L) 1.80 ± 1.21 1.60 ± 1.05 .106
 INR 1.17 ± 0.18 1.17 ± 0.15 .774
 APRI 1.17 ± 1.58 1.52 ± 3.31 .275
 FIB-4 2.16 ± 1.67 2.69 ± 3.42 .117
Histologic activity grade    .271
 A0 27 (20.5) 23 (19.2) .875
 A1 49 (37.1) 57 (47.5) .099
 A2 40 (30.3) 32 (26.7) .577
 A3 16 (12.1) 8 (6.7) .197
Histologic fibrosis stage    .787
 F0 11 (8.3) 10 (8.3) > .99
 F1 16 (12.1) 21 (17.5) .285
 F2 25 (18.9) 21 (17.5) .871
 F3 29 (22.0) 22 (18.3) .531
 F4 51 (38.6) 46 (38.3) .961
TE (kPa) 11.13 ± 5.21 11.05 ± 5.87 .914
CK18 (ng/L) 105.41 ± 28.33 103.24 ± 26.67 .533
  1. Except where indicated, data are numbers of patients, with percentages in parentheses
  2. ALT, alanine transferase; ALP, alkaline phosphatase; APRI, aspartate transaminase-to-platelet ratio; AST, aspartate transaminase; BMI, body mass index; CK18, cytokeratin 18; FBG, fasting blood glucose; FINS, fasting insulin; FIB-4, fibrosis-4 index; GGT, γ-glutamyl transferase; INR, international normalized ratio; TE, transient elastography; TG, triglyceride; WBC, white blood cell
  3. aData are presented as means ± standard deviations